Filing Flows › Companies › Royalty Pharma › Timeline
Royalty Pharma stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+68.1% to $67.30
Royalty Pharma (RPRX) stock rose 68% over the last 252 sessions, to $67.30. On the way it reported 4 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside) and 12 Form 144 notices of planned sales, and the company filed 2 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026 | Earnings | Earnings: beat the EPS estimate by 2.4% | +1.7% (+0.1% vs SPY) | — | — |
| Oct 5, 2026 | Form 144 | Form 144: Marshall Urist plans to sell $236K | −0.9% (−1.5% vs SPY) | −0.4% (−1.6% vs SPY) | +15.1% (+17.5% vs SPY) |
| Sep 28, 2026 | Form 144 | Form 144: Marshall Urist plans to sell $239K | +0.3% (+1.0% vs SPY) | −1.8% (−1.6% vs SPY) | +10.6% (+11.4% vs SPY) |
| Sep 22, 2026 | Form 144 | Form 144: SCH Investment Partners LLC plans to sell $5.8M | +0.1% (+0.2% vs SPY) | −0.1% (+0.9% vs SPY) | +6.3% (+6.9% vs SPY) |
| Aug 18, 2026 | Form 144 | Form 144: SCH Investment Partners LLC plans to sell $6.0M | +0.4% (+1.1% vs SPY) | +3.1% (+4.3% vs SPY) | −1.7% (+0.8% vs SPY) |
| Aug 13, 2026 | Form 144 | Form 144: Terrance Coyne plans to sell $644K | −1.1% (−1.8% vs SPY) | +4.6% (+5.0% vs SPY) | −0.6% (+0.4% vs SPY) |
| Aug 12, 2026 | Form 144 | Form 144: Errol B. De Souza plans to sell $7.2M | +2.4% (+2.2% vs SPY) | +3.6% (+4.0% vs SPY) | +2.1% (+3.7% vs SPY) |
| Aug 12, 2026 | Form 144 | Form 144: Errol B. De Souza plans to sell $11.9M | +2.4% (+2.2% vs SPY) | +3.6% (+4.0% vs SPY) | +2.1% (+3.7% vs SPY) |
| Aug 5, 2026 | Earnings | Earnings: beat the EPS estimate by 3.9% | +0.5% (+0.7% vs SPY) | +0.5% (+0.6% vs SPY) | +9.7% (+10.5% vs SPY) |
| Jul 1, 2026 | Form 144 | Form 144: Marshall Urist plans to sell $508K | −0.5% (−0.4% vs SPY) | +4.0% (+4.2% vs SPY) | +5.1% (+5.8% vs SPY) |
| Jun 30, 2026 | Form 144 | Form 144: SCH Investment Partners LLC plans to sell $5.7M | −1.8% (−2.6% vs SPY) | +1.2% (+0.3% vs SPY) | +3.6% (+5.2% vs SPY) |
| Jun 24, 2026 | Form 144 | Form 144: Marshall Urist plans to sell $502K | −2.0% (−1.9% vs SPY) | +1.3% (−0.5% vs SPY) | +6.4% (+5.8% vs SPY) |
| Jun 23, 2026 | Form 144 | Form 144: SCH Investment Partners LLC plans to sell $8.2M | +3.3% (+4.7% vs SPY) | +6.4% (+6.8% vs SPY) | +9.2% (+8.8% vs SPY) |
| Jun 23, 2026 | Form 144 | Form 144: Christopher Hite plans to sell $1.7M | +3.3% (+4.7% vs SPY) | +6.4% (+6.8% vs SPY) | +9.2% (+8.8% vs SPY) |
| May 28, 2026 | 8-K | Material definitive agreement | +2.3% (+2.1% vs SPY) | +1.0% (+0.6% vs SPY) | +4.7% (+6.2% vs SPY) |
| May 6, 2026 | Earnings | Earnings: beat the EPS estimate by 9.4% | +0.6% (−0.8% vs SPY) | +2.5% (+0.5% vs SPY) | +9.1% (+4.6% vs SPY) |
| Feb 11, 2026 | Earnings | Earnings: beat the EPS estimate by 10.0% | +0.1% (+0.1% vs SPY) | +2.5% (+3.4% vs SPY) | +4.2% (+8.1% vs SPY) |
| Dec 22, 2025 | 8-K | Directors and officers: departures, appointments, pay | +1.4% (+0.9% vs SPY) | +0.3% (0.0% vs SPY) | +3.9% (+3.2% vs SPY) |
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Royalty Pharma: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.